MapLight Therapeutics Inc. (MPLT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

MPLT scores 35 out of 100 and receives a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -32.4%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and institutional flow, which together indicate that the reported losses and negative free cash flow are not yet offset by a demonstrated earnings path or sponsorship from large holders. The forensic balance sheet pillar is the strongest of the five but still sits at half its maximum, reflecting a Piotroski F-Score of 2 out of 9. The Beta of 1.0 means the stock is rated as moving in line with the broader market, so macro regime fit does little to differentiate it. Any upside case would rest on catalysts rather than on current cash generation, and the balance of evidence in this rating points toward elevated risk to the equity relative to its reported fundamentals.

MapLight Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company has a market capitalization of $0.5B. — describes its specific products, customers, or revenue model.

Operating and net losses widened from FY 2024 to FY 2025, and free cash flow was negative in both periods. Gross, operating, and net margins are each reported as 0% in the market data. ROIC is -32.4% and the Altman Z-Score is 2.5, while the Piotroski F-Score is 2 out of 9 and Debt/Equity is 0.5. Cash rose from $38.3M to $46.

• 🐂 Primary Bull Case: The company's Nobel-linked co-founder news and a 52-week range that sits well below the high may attract a rebound if cash is extended beyond the $46.7M balance. With Fundamental Cash Engine at 8/20 (ROIC -32.4%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $7.44 – $40.43 52-week range.
• 🐻 Primary Bear Case: Negative free cash flow of -$138.6M against $46.7M of cash, ROIC of -32.4%, and a Piotroski F-Score of 2 out of 9 leave the equity exposed to dilution or further balance sheet strain. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Upstream suppliers, downstream customers, and cross-sector dependencies are — For a prospective investor, the practical implication is that the source data cannot map second-order ripples from suppliers, partners, or customers.6M against cash of $46.7M.

• Key Question #1: What is the amount and terms of any debt, since the Debt field is N/A for both periods despite a Debt/Equity ratio of 0.5?
• Key Question #2: What is the institutional and insider ownership profile, given that holders data is NONE?
• Key Question #3: How sensitive is MPLT's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?